ArticleBlood cancer journal2017
Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma.
Article in Blood cancer journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 33 citations in OpenAlex.
- Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies.Blood cancer journal · 2024Trial
- Awareness and Utilization of the Revised Second International Staging System (R2-ISS) and 1q21 Gain/Amplification Testing: A Nationwide Web-Based Survey of Hematologists in Japan.Cancer medicine · 2026Article
- Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation.British journal of haematology · 2024Article
- Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma.Haematologica · 2023Article
- Review
- Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee.Blood cancer journal · 2022Review
- A simple additive staging system for newly diagnosed multiple myeloma.Blood cancer journal · 2022Article
- Factors associated with adherence to guidelines in cancer pain management among adult patients evaluated at oncology unit, in the University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia.Frontiers in pain research (Lausanne, Switzerland) · 2022Article
- miR-451a suppression of IL-6R can inhibit proliferation and increase apoptosis through the JAK2/STAT3 pathway in multiple myeloma.Oncology letters · 2020Article
- Circulating miR-451a levels as a potential biomarker to predict the prognosis of patients with multiple myeloma.Oncology letters · 2020Article
- Serum-free light chains combined with the Revised International Staging System could further distinguish the superior and inferior clinical outcome of multiple myeloma patients.Annals of hematology · 2020Article
- Article
- Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis.Blood cancer journal · 2020Article
- Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma.British journal of haematology · 2019Article
- Article
- Article
- The multiple myelomas - current concepts in cytogenetic classification and therapy.Nature reviews. Clinical oncology · 2018Review
- Analysis of the Metabolic Characteristics of Serum Samples in Patients With Multiple Myeloma.Frontiers in pharmacology · 2018Article
- The Role ofContrast media & molecular imaging · 2018Article
- The effect of novel therapies in high-molecular-risk multiple myeloma.Clinical advances in hematology & oncology : H&O · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 1 institution in 1 country.
Funding
Abstract
We analyzed the utility of Revised International staging system (RISS) in an unselected cohort of newly diagnosed multiple myeloma (NDMM; cohort 1), and relapsed/refractory multiple myeloma (RRMM; cohort 2) patients. Cohort 1 included 1900 patients seen within 90 days of diagnosis, from 2005 to 2015, while cohort 2 had 887 patients enrolled in 23 clinical trials at Mayo Clinic. The overall survival (OS) and progression-free survival (PFS) was calculated from the time since diagnosis or trial registration. The median estimated follow up was 5 and 2.3 years for Cohorts 1 and 2, respectively. Among 1067 patients evaluable in Cohort 1, the median OS and PFS was 10 and 2.8 years for RISS stage I, 6 and 2.7 years for RISS stage II and 2.6 and 1.3 years for RISS stage III (P<0.0001). Among 456 patients evaluable in Cohort 2, the median OS and PFS was 4.3 and 1.1 years for RISS stage I, 2 and 0.5 years for RISS stage II and 0.8 and 0.2 years for RISS stage III (P<0.0001). In conclusions, RISS gives a better differentiation of NDMM as well as RRMM patients into three survival subgroups and should be used to stratify patients in future clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.